Previous Close | 2.3300 |
Open | 2.3500 |
Bid | 2.3200 x 4000 |
Ask | 2.4100 x 800 |
Day's Range | 2.3200 - 2.4000 |
52 Week Range | 1.0300 - 4.1500 |
Volume | |
Avg. Volume | 189,724 |
Market Cap | 103.417M |
Beta (5Y Monthly) | 0.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6800 |
Earnings Date | Mar 06, 2023 - Mar 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CTSO
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has appointed Irina B. Kulinets, Ph.D., as Senior Vice President of Global Regulatory Affairs. Dr. Kulinets brings more than 30 years of experience in regulatory affairs and clinical research of medical devices, biologics, and combination products in multiple t
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...